ReviewThe Lancet. Oncology2022
Clinical advances in PET-MRI for breast cancer.
Review in The Lancet. Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- A Randomized, Phase II Clinical Trial of FLT-PET and FDG-PET for Early Response Assessment of Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- AI-Assisted Tumor Boundary Delineation via Targeted Ultrasmall Iron Oxide Nanoprobe for High-Contrast HER2-Positive Tumor Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- ASO Author Reflections: Visions in Axilla Management with Clinical Advances in LymphPET for Breast Cancer.Annals of surgical oncology · 2026Article
- Hybrid [Bioengineering (Basel, Switzerland) · 2026Article
- Uptake Patterns of [Cancers · 2026Article
- Diagnostic accuracy of modern imaging following neoadjuvant therapy for breast cancer: a comparative analysis of ultrasound versus [18F] FDG PET/MRI in breast response assessment.Frontiers in oncology · 2026Article
- Evaluation of Diagnostic Accuracy of Combined Ultrasound Elastography and Magnetic Resonance Imaging in Breast Cancer.Breast cancer (Dove Medical Press) · 2026Article
- Understanding Immune Cell Adaptation to Tumor Hypoxia for Maximized Therapeutic Efficacy of Immunotherapy: Biology and Non-invasive Imaging Application.Cancer research and treatment · 2026Review
- IL-6, IL-8, and IL-17A as predictive biomarkers for treatment response to PD-1 blockade immunochemotherapy in advanced gastric cancer.Archives of medical science : AMS · 2026Article
- Comparison of Magnetic Resonance Spectra Acquired With Hybrid PET/MR and Standalone MR Scanners.Journal of magnetic resonance imaging : JMRI · 2025Article
- Application of CAD Systems in Breast Cancer Diagnosis Using Machine Learning Techniques: An Overview of Systematic Reviews.Bioengineering (Basel, Switzerland) · 2025Review
- Multimodal imaging and advanced quantitative techniques for HER-2 status prediction in breast cancer.Discover oncology · 2025Review
- Assessment of surgical precision and safety in oncoplastic breast-conserving surgery for breast cancer under the guidance of imaging.BMC surgery · 2025Article
- Deep learning in nuclear medicine: from imaging to therapy.Annals of nuclear medicine · 2025Review
- Optimizing Deep Learning Models for Luminal and Nonluminal Breast Cancer Classification Using Multidimensional ROI in DCE-MRI-A Multicenter Study.Cancer medicine · 2025Article
- The Use of Positron-Emission Tomography-Magnetic Resonance Imaging to Improve the Local Staging of Disease in Myxofibrosarcoma: A Feasibility Study.Diagnostics (Basel, Switzerland) · 2025Article
- Article
- Radiomics analysis of thoracic vertebral bone marrow microenvironment changes before bone metastasis of breast cancer based on chest CT.Journal of bone oncology · 2025Article
- Article
- 18F-FDG PET/CT for early prediction of pathological complete response in breast cancer neoadjuvant therapy: a retrospective analysis.The oncologist · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Imaging is paramount for the early detection and clinical staging of breast cancer, as well as to inform management decisions and direct therapy. PET-MRI is a quantitative hybrid imaging technology that combines metabolic and functional PET data with anatomical detail and functional perfusion information from MRI. The clinical applicability of PET-MRI for breast cancer is an active area of research. In this Review, we discuss the rationale and summarise the clinical evidence for the use of PET-MRI in the diagnosis, staging, prognosis, tumour phenotyping, and assessment of treatment response in breast cancer. The continued development and approval of targeted radiopharmaceuticals, together with radiomics and automated analysis tools, will further expand the opportunity for PET-MRI to provide added value for breast cancer imaging and patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.